Mahlokozera, Tatenda
Patel, Bhuvic http://orcid.org/0000-0001-8062-7310
Chen, Hao
Desouza, Patrick
Qu, Xuan http://orcid.org/0000-0003-1436-3315
Mao, Diane D.
Hafez, Daniel
Yang, Wei
Taiwo, Rukayat
Paturu, Mounica
Salehi, Afshin
Gujar, Amit D. http://orcid.org/0000-0003-0689-6680
Dunn, Gavin P.
Mosammaparast, Nima http://orcid.org/0000-0001-5453-5914
Petti, Allegra A. http://orcid.org/0000-0001-6884-6107
Yano, Hiroko http://orcid.org/0000-0001-6548-0920
Kim, Albert H. http://orcid.org/0000-0002-1751-8493
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS094670)
Article History
Received: 7 September 2020
Accepted: 18 October 2021
First Online: 3 November 2021
Competing interests
: A.H.K. is a consultant for Monteris Medical and has received research grants from Monteris Medical for a mouse laser therapy study as well as from Stryker and Collagen Matrix for clinical outcomes studies about a dural substitute, which have no direct relation to this study. G.P.D. is a founder and holds equity in Immunovalent Therapeutics. The remaining authors declare no competing interests.